Truist Financial Corp Sells 27,679 Shares of Danaher Corporation $DHR

Truist Financial Corp trimmed its holdings in Danaher Corporation (NYSE:DHR) by 7.8% in the third quarter, Holdings Channel reports. The institutional investor owned 326,593 shares of the conglomerate’s stock after selling 27,679 shares during the period. Truist Financial Corp’s holdings in Danaher were worth $64,750,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in DHR. WFA of San Diego LLC acquired a new position in Danaher in the 2nd quarter valued at $26,000. Howard Hughes Medical Institute acquired a new stake in shares of Danaher during the 2nd quarter worth $27,000. TruNorth Capital Management LLC bought a new position in shares of Danaher in the third quarter worth $28,000. Red Tortoise LLC raised its stake in Danaher by 175.0% in the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after purchasing an additional 98 shares in the last quarter. Finally, Tripletail Wealth Management LLC acquired a new position in Danaher in the third quarter valued at about $31,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DHR. Rothschild Redb downgraded shares of Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. JPMorgan Chase & Co. increased their price target on shares of Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Redburn Partners set a $220.00 price objective on shares of Danaher in a research note on Wednesday, October 8th. Evercore ISI restated an “outperform” rating and set a $254.00 target price on shares of Danaher in a research note on Wednesday. Finally, Deutsche Bank Aktiengesellschaft raised their target price on Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Twenty research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $252.70.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q4 beat — Danaher reported $2.23 EPS (above consensus) and $6.84B revenue, with revenue up ~4.5% year‑over‑year, showing underlying operational strength. Danaher Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Bioprocessing and diagnostics led growth — management flagged life‑sciences/bioprocessing strength as a driver and analysts point to upside from bioprocessing exposure. Danaher Q4 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
• Neutral Sentiment: FY‑2026 guidance came in essentially in‑line (EPS 8.350–8.500 vs. consensus ~8.42); management described a gradual improvement in end‑market conditions rather than an immediate acceleration. Danaher forecasts 2026 profit in line with estimates on pharma spending recovery
• Neutral Sentiment: Management emphasized cash strength and a balanced result, which supports financial flexibility but did not materially change capital allocation or upside expectations. Danaher Earnings Call: Cash Strength Amid Cautious Outlook
• Negative Sentiment: Shares sold off despite the beat — investors likely disappointed by the cautious tone and guidance that was only inline, leading to profit‑taking after a recent run toward the 1‑year high; rich valuation (PE ~46) magnifies sensitivity to any lack of upside. Danaher Expects Gradual Improvement In End-Market Conditions

Danaher Stock Down 5.0%

Shares of DHR opened at $224.00 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $242.80. The stock has a market capitalization of $158.22 billion, a price-to-earnings ratio of 46.19, a PEG ratio of 3.59 and a beta of 0.89. The stock has a fifty day moving average of $230.83 and a 200-day moving average of $213.77.

Danaher (NYSE:DHR) last issued its earnings results on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.09. The business had revenue of $6.84 billion during the quarter, compared to analysts’ expectations of $6.79 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.14 EPS. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. As a group, sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, December 26th. Danaher’s dividend payout ratio (DPR) is 26.39%.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the sale, the senior vice president directly owned 2,625 shares of the company’s stock, valued at $552,352.50. The trade was a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the transaction, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. The trade was a 59.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,248 shares of company stock worth $6,609,663 in the last ninety days. Company insiders own 11.20% of the company’s stock.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.